TK 002 - Pyxis Oncology/Jiangsu T-mab BioPharma
Alternative Names: APX 002; TK 002 - Pyxis Oncology/Jiangsu T-mab BioPharmaLatest Information Update: 24 Aug 2023
At a glance
- Originator Epitomics
 - Developer Jiangsu T-mab BioPharma; Pyxis Oncology
 - Class Monoclonal antibodies
 - Mechanism of Action Interleukin 1 beta inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- No development reported Inflammation
 
Most Recent Events
- 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology
 - 28 Feb 2023 No recent reports of development identified for preclinical development in Inflammation in China (Parenteral)
 - 28 Jan 2021 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)